Related Experiment Video
Updated: Jul 25, 2025
07:59
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
15.0K
Immunoinformatics Strategy to Develop a Novel Universal Multiple Epitope-Based COVID-19 Vaccine
Nizar A Khamjan1, Mohtashim Lohani2,3, Mohammad Faheem Khan4
1Department of Medical Laboratories Technology, College of Applied Medical Sciences, Jazan University, Jazan 45142, Saudi Arabia.
Vaccines
|June 28, 2023
Summary
This study designed a novel broad-spectrum COVID-19 vaccine using conserved regions of the SARS-CoV-2 nucleocapsid protein. Computational analysis shows promising immunogenicity and global population coverage for preventing infection and transmission.
Area of Science:
- Vaccinology
- Computational Biology
- Immunology
Background:
- Current COVID-19 vaccines reduce severity but do not prevent SARS-CoV-2 transmission or reinfection.
- Emerging SARS-CoV-2 variants necessitate broader-spectrum vaccines for lasting protection.
- The nucleocapsid (N) protein is highly expressed and immunogenic during early SARS-CoV-2 infection.
Purpose of the Study:
- To design a novel, broad-spectrum vaccine targeting conserved regions of the SARS-CoV-2 nucleocapsid protein.
- To predict and select immunogenic B-cell and T-cell epitopes for vaccine development.
- To computationally evaluate the vaccine construct's immunogenicity, antigenicity, and population coverage.
Main Methods:
- Utilized bioinformatics to identify conserved N protein regions from prevalent SARS-CoV-2 strains.
- Predicted and filtered B- and T-cell epitopes based on immunogenicity, antigenicity, and toxicity.
- Constructed a multi-epitope vaccine candidate using specific linkers (EAAAK, AAY, GPGPG).
- Simulated immune response and assessed population coverage using computational models.
- Cloned the chimeric protein construct into a Pet28a/Cas9-cys vector for expression screening in *Escherichia coli*.
Main Results:
- Identified and combined effective epitopes into a multi-epitope construct with high immunogenic potential.
- Computational simulations indicated positive immune response stimulation and broad global population coverage.
- Successful cloning and detection of potential chimeric protein expression in *E. coli*.
Conclusions:
- The developed multi-epitope vaccine candidate demonstrates significant promise in silico for controlling SARS-CoV-2.
- Further experimental testing is warranted to validate its efficacy in preventing infection and transmission.
- This computational approach offers a viable strategy for developing next-generation vaccines against evolving SARS-CoV-2 strains.
